For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

singup link button why should I sign up?
Phase Ib Study with Reparixin plus Paclitaxel in HER-2 Negative Breast Cancer.
Breast Cancer ( Malignant tumor of breast )
Location of study visits: Ann Arbor, MI
The purpose of this study is to see if the study drug reparixin helps to inhibit the growth of tumors.
This study is looking for: female  Only women
  • Volunteers with specific conditions
  • More than 18 years old
The purpose of this study is to see if the study drug reparixin helps to inhibit the growth of tumors.
16 HEROES have already shown interest in this study. I am interested Print Study | Email Study
Who can participate?
What is involved? Reparixin is a new drug which has been studied at the University of Michigan in animal models of breast cancer and has been shown to lower the levels of cancer stem cells in tumors and to inhibit the further growth of the tumor. We do not know whether reparixin can have these effects in humans and we do not know if the drug is safe for use in humans when combined with chemotherapy. Reparixin is an experimental drug which means it has not been approved by the FDA. The objectives of this study are to learn more about possible side effects of the study drug reparixin, study different dose levels of the drug and the effects it may have on your disease and to study markers for cancer cells, in particular for cancer stem cells.
Compensation This study does not offer any compensation.
More about the study

IRB number: HUM00052808
Activation Date: 01/24/2014    Deactivation Date: 07/01/2014
Study Team Principal Investigator:  Schott, Anne F Department:  Internal Medicine - Hematology & Oncology
Related Research Studies More results >
We respect your privacy! UMClinicalStudies.org is a secure, password-protected database. All the information that you choose to share will be kept private and confidential. Read University of Michigan's Notice of Privacy Practices.